Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion

TLDR Exact Sciences is being acquired by Abbott Laboratories for $105 per share in cash, representing a 21.8% premium The deal values Exact Sciences at approximately $21 billion in equity value, with total transaction value reaching $23 billion including debt Exact Sciences’ flagship products Cologuard and Oncotype DX will join Abbott’s diagnostics portfolio The company [...]

The post Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion appeared first on Blockonomi.